Next Page
What is INQOVI?
There’s no
place like home
INQOVI® (decitabine and cedazuridine) tablets—the only oral hypomethylating agent (HMA) for the treatment of myelodysplastic syndromes (MDS), including CMML.
INQOVI can allow patients to take their therapy in the convenience and comfort of their own home or wherever they are.1
CMML=chronic myelomonocytic leukemia.
Who is INQOVI for?
INQOVI is indicated for treatment of adult patients with myelodysplastic syndromes (MDS), including1:
- previously treated and untreated, de novo and secondary MDS with the following French‑American‑British subtypes:
- refractory anemia
- refractory anemia with ringed sideroblasts
- refractory anemia with excess blasts
- chronic myelomonocytic leukemia
- intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups
Decitabine and cedazuridine (INQOVI®) is the only
FDA-approved oral HMA option in MDS (IPSS Intermediate-1 and above) that the NCCN recommends could be a substitution for IV decitabine1,2
Oral decitabine and cedazuridine (DEC-C) (Category 2A*) could be a substitution for intravenous decitabine in patients with IPSS intermediate-1 and above in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Myelodysplastic Syndromes.
- Do not substitute decitabine and cedazuridine (INQOVI) for an IV decitabine product within
a cycle.1
*Category 2A: Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.
2. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Myelodysplastic Syndromes V.3.2022. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed April 22, 2022. To view the most recent and complete version of the guideline, go online to NCCN.org.
NCCN makes no warranties of any kind whatsoever regarding their content, use, or application, and disclaims any responsibility for their application or use in any way.